Sign In
Last checked at 
22 Jul 2010 12:24
ο»Ώ
Β
Β
Β
Β
Β
Thursday 22 July 2010
Β
Β
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Β
Notification of Preliminary Results and Trading update
Β
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, will announce its preliminary results for the year ended 30 June 2010 on 20 September 2010. The Company expects to report revenue of approximately Β£40.7m (2009: Β£37.8m); broadly in-line with current market expectations.
Β
Significantly, for the first time as a public company, Allergy Therapeutics expects to post an operating profit for the financial year ended 30 June 2010 (2009: loss of Β£6.2m). Full details of the company's performance will be made available in the preliminary announcement.
Β
Commenting on the trading update, Manuel Llobet, CEO of Allergy Therapeutics said:
Β
"This is great news for the Company, posting its maiden operating profit and will be a landmark in the Company's performance"
Β
Β
For further information
Β
|
Allergy Therapeutics |
+44 (0) 1903 845 821 |
|
Ian Postlethwaite Finance Director |
|
|
Manuel Llobet Chief Executive Officer |
|
|
|
|
|
www.allergytherapeutics.com |
|
|
|
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson/ Clare Terlouw |
|
|
|
|
|
|
|
|
|
|
Β
Β
Follow the stocks
